This page is part of our 2021 average annual return archive: it shows the ELYM Average Annual return Since for calendar year 2021. This metric helps investors evaluate and compare performance among different stocks, over time.
Average annual return should be reviewed alongside overall market trends, and company fundamentals like earnings and revenue. As the saying goes on Wall St., past performance from 2021 does not guarantee future similar returns.
| ELYM Average Annual Return Chart Since 2021 | |||
Also see: • ELYM stock yearly return 2022 • ELYM stock yearly return 2023 • ELYM YTD return | |||
| Average Annual Return Benchmarks |
|
Compare ELYM average annual return versus benchmarks: S&P Average Annual Return Dow Average Annual Return Nasdaq 100 Average Annual Return Russell 2000 Average Annual Return Gold Average Annual Return 10 Year Treasury Average Annual Return |
| ELYM Share Performance |
| ELYM Average Annual Return Table Since 2021 | ||||||||||||||||||||||||||||||
ELYM average annual return is presented with the assumption of reinvestments of any dividends on ex-date. |
| About Eliem Therapeutics Inc |
| Eliem Therapeutics is a clinical-stage biotechnology company focused on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Co. is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with therapeutic potential to deliver therapeutics for patients with these disorders. Co.'s two clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide prodrug for the treatment of diabetic peripheral neuropathic pain and lumbosacral radicular pain, commonly referred to as sciatica. The ELYM average annual return since 2021 is shown above.
The Average Annual Return on the ELYM average annual return since 2021 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends. Thus, researching Average Annual Returns is good practice for investors — whether ELYM average annual return since 2021 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the ELYM average annual return calculation with any dividends reinvested as applicable (on ex-dates). |
| ELYM Current Stock Quote |
 Free ELYM Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Don't Forget Dividends in Average Annual Return! | |
|
| Average Annual Return Peers |
| Eliem Therapeutics (ELYM) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:
EMBC Average Annual Return |
Video: Don't Forget Dividends in Average Annual Return!